INTRODUCTION
Extramammary Paget disease (EMPD) is a rare adenocarcinoma in situ that originates in skin that contains apocrine glands. The exact incidence is unknown, and the vulva is the most common site of occurrence. EMPD is associated with invasive cancer in 4% to 20% of patients. 1 In a series of 1,439 patients with invasive EMPD, 80.4% had localized disease, 17.1% had locoregional spread, and only 2.5% presented with distant disease. 2 Treatment is primarily surgical, but EMPD frequently is multicentric, and relapses are common regardless of treatment modality. Prognosis is poor when distant or regional lymph node metastases are present. One retrospective study reported a 5-year survival of 100% in the sentinel lymph node negative group but only 24% in the sentinel lymph node positive group. 3 Other adverse prognostic factors are tumor thickness > 4 mm, lymphovascular space invasion, and distant disease. 4 We present the case of a patient, heavily pretreated with prior progression on trastuzumab, with a large primary tumor and metastatic invasive EMPD who experienced a complete clinical response with ado trastuzumab emtansine (TDM1 [KADCYLA; Genentech, San Francisco, CA]), a human epidermal growth factor receptor 2 (HER2)-targeted antibody and microtubule inhibitor conjugate.
CASE REPORT
The patient is a 65-year-old woman who had been treated during the past 16 years for multiple locoregional recurrences of EMPD of the vulva. Since 2002, she underwent six excisional procedures, three laser ablations, several courses of topical imiquimod treatment, external beam vulvar radiation to a dose of 56 Gy to the perineum and the left-side inguinal nodes, and interstitial brachytherapy to 30 Gy. Her treatment was complicated by urethral swelling and eventually obstruction, requiring placement of a temporary suprapubic catheter and urethral reconstruction in late 2014.
In early 2016, the patient noted worsening urinary retention, and a computed tomography (CT) urogram demonstrated two centrally hypodense liver lesions that measured up to 2.2 cm, multiple enlarged retroperitoneal lymph nodes, and a circumferential soft tissue mass that infiltrated the cervix and upper vagina. Intense fluorodeoxyglucose (FDG) avidity in these masses was seen on positron emission tomography (PET)/ CT scanning. On examination under anesthesia, a Paget lesion obliterated the perineum, including the urethra, vulva, and perianal area, and vaginoscopy was required to visualize the cervix. A suprapubic catheter was placed again because of urethral occlusion. Vulvar biopsy specimens confirmed invasive, poorly differentiated adenocarcinoma that had arisen from EMPD, with extensive lymphovascular space invasion and 3+ HER2 immunostaining in > 10% of cells (Fig  1) with trastuzumab added from cycles 2 to 6. The standard dosing of trastuzumab 8 mg/kg was given with the first dose and 6 mg/kg with subsequent doses. Chemotherapy was tolerated without dose reductions or delays. Screening echocardiograms were unremarkable and stable throughout treatment. A radiographic complete response to treatment was found on PET/CT scan after six cycles. She continued with five cycles of trastuzumab maintenance therapy. Repeat PET/CT scanning after 3 months of maintenance therapy revealed an intensely FDG-avid recurrent cervical and vaginal tumor and mildly enlarged and FDG-avid left-side external iliac nodes. Progression-free survival with trastuzumab, carboplatin, and paclitaxel followed by trastuzumab maintenance was 7.0 months.
The patient was counseled about a lack of conventional treatment options and consented to TDM1 therapy on the basis of a strong rationale for a potential benefit without expected severe toxicity. She started TDM1 at the standard dose of 3.6 mg/kg every 21 days. From the end of 2016 to spring 2017, she received six cycles of TDM1. After cycle 1, the patient reported that her lesions were drier, less painful, and less irritated and that vaginal discharge had decreased. Treatment was well tolerated, with toxicity limited to grade 1 fatigue and grade 1 bleeding, including intermittent vaginal bleeding, hematuria, epistaxis, and gum bleeding, which started after cycle 2. No cardiotoxicity was found on routine screening echocardiograms. Follow-up PET/ CT scans were notable for markedly decreased size and metabolic activity of the primary pelvic lesion after cycle 3 and for complete resolution of disease on imaging after cycle 6 (Fig 2) . The patient experienced recurrence, however, 6 months after starting TDM1.
DISCUSSION
In patients with invasive EMPD and distant metastases, no standard chemotherapy regimen has been established. Case reports have described the use of various combinations, including fluorouracil, mitomycin C, platinum-based agents, and hormonal suppression with letrozole. 6, 7 Although insufficient data exist on the application of the current breast cancer ASCO-CAP HER2 testing guidelines 8 to other cancer types, the amplification of HER2 has been described in many cases of invasive EMPD (Table 1) . Multiple large, multicenter trials have firmly established the benefit of trastuzumab in the treatment of metastatic HER2-positive breast cancer, 9 which has led to consideration of trastuzumab in the treatment of invasive metastatic HER2-amplified EMPD.
Retrospective data have suggested that HER2 overexpression is higher in patients with invasive EMPD than with noninvasive EMPD. 19 Furthermore, a significant correlation has been demonstrated among the presence of invasion, lymph node metastasis, and HER2 overexpression. A hypermetabolic cervical mass (arrow) was seen with associated hydrometra, which had complete treatment response to chemotherapy. 30 TDM1 combines the mechanism of action as described for trastuzumab with the added clinical benefit of delivering the intracellular antimicrotubular agent DM1 into the HER2-overexpressing tumor cells by receptor-mediated endocytosis. 31 TDM1 is well tolerated, with the most common reported adverse events being fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, constipation, transaminitis, and epistaxis, 32 and the median time to a clinically meaningful decrease in quality of life is 7.7 months. 33 In patients with HER2-positive breast cancer with disease progression on trastuzumab, TDM1 has been shown to be an effective treatment option. The EMILIA (Emtansine Versus Capecitabine Plus Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer) trial found an objective response rate of 43.6% and median progression-free survival of 9.6 months after TDM1 treatment in patients with HER2-positive metastatic breast cancer and prior progression on trastuzumab. 34 The TH3RESA trial similarly confirmed the superiority of TDM1 over physician's choice of chemotherapy in patients with breast cancer with previous progression on trastuzumab and lapatinib, with a median overall survival benefit of 6.9 months. 35 TDM1 was approved by the Food and Drug Administration in 2013 for the treatment of HER2-positive metastatic breast cancer with HER2 overexpression in patients who have previously received trastuzumab and a taxane either separately or in combination.
On the basis of the current patient's immunohistochemical staining and prior response but later progression on trastuzumab, TDM1 was selected for the treatment of her recurrent invasive EMPD. Although TDM1 has been shown to be efficacious in patients with breast cancer with HER2-overexpressed malignancy unresponsive to trastuzumab, disease response has not been consistently demonstrated with other tumor types. The GATSBY trial showed that TDM1 was not superior to taxane chemotherapy 4 ascopubs.org/journal/po JCO™ Precision Oncology in HER2-positive unresectable gastric or gastroesophageal junction cancers with prior HER2-targeted therapy. 36 The current patient's favorable response indicates that in HER2-positive invasive EMPD, TDM1 may be considered a viable treatment option. In addition, in hormone receptor-and HER2-positive breast cancer, dual targeting of both signaling pathways may improve outcomes significantly. 37 In breast cancer, bidirectional cross talk between the estrogen receptor and HER2 pathways likely contributes to anti-HER2 therapy resistance. Preclinical models with breast cancer cell lines have demonstrated a benefit to simultaneous hormone and HER2 therapy over HER2-targeted therapy alone, but no phase II or III trials have compared the two. 38 The TANDEM trial demonstrated a 2.4-month survival benefit in postmenopausal patients with metastatic breast cancer who received anastrazole and trastuzumab versus hormonal therapy with anastrazole alone. 39 Hormone receptor immunohistochemistry was not examined in the current patient, but dual inhibition may be a theoretically superior strategy for treating hormone receptor and HER2-positive invasive EMPD.
One limitation to this study is that the ASCO-CAP HER2 testing guidelines have not been routinely adopted or validated for tissues other than breast carcinoma; thus, the HER2 immunohistochemistry results may not be consistent or reliable in this tumor type. Molecular subtyping has been used increasingly to find appropriate targeted therapies and may be more reliable than immunohistochemistry. 23 Vornicova et al 7 reported a partial response that lasted 12 months in a male with adenocarcinoma with Paget disease and negative HER2 testing by both immunohistochemistry and FISH, but received anti-HER2 therapy on the basis of tumor somatic mutation testing alone (Table 2 ).
In light of the poor prognosis with metastatic EPMD, paucity of treatment options, high incidence of HER2 amplifications in EMPD, and favorable adverse effect profile of TDM1, we suggest HER2 testing and consideration of TDM1 treatment in patients with HER2-overexpressed invasive EMPD who experience treatment failure with trastuzumab. Additional investigation is needed to clarify which patients are the best candidates for TDM1 treatment and their anticipated response rates. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center .
